Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Rad Laboratories Closes $1.2B Senior Notes Offering

NEW YORK – Bio-Rad Laboratories announced on Wednesday the closing of a public offering of $1.2 billion aggregate senior notes.

The firm intends to use the net proceeds from the offering for general corporate purposes, including working capital and capital expenditures, as well as possibly investments in and acquisitions of other companies, products, or technologies.

The notes were issued as $400 million due in 2027 and $800 million due in 2032. The five-year notes have an annual rate of 3.3 percent, and the 10-year notes have an annual rate of 3.7 percent, Bio-Rad said.

Citigroup Global Markets, Goldman Sachs, and JP Morgan Securities acted as joint bookrunning managers for the offering.

Bio-Rad recently described its progress in restructuring its business and its near-term goal of accelerating growth. It expects a 9 percent compound annual growth rate through 2025 in its core business, driven by increased focus on biopharma and the Asia-Pacific market as well as a pipeline of new product offerings. Bio-Rad also recently emphasized its increased appetite for a larger, potentially transformative M&A deal.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.